Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as "Zydus") has received final approval for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA).
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).
The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 482.30 as compared to the previous close of Rs. 480.50. The total number of shares traded during the day was 28350 in over 1350 trades.
The stock hit an intraday high of Rs. 486.50 and intraday low of 471.10. The net turnover during the day was Rs. 13712152.00.
(*as of 31st December 2022)